uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease
~ FDA sets PDUFA target action date of May 1, 2027 ~
~ FDA sets PDUFA target action date of May 1, 2027 ~